
ğŸ¬ YouTube Script: â€œShould I Give My Cat Rapamycin for HCM?â€

[Opening Scene â€” VetCardioHub logo animation + soft music]
â€¨â€œWelcome to VetCardioHub â€” where we explore the heart of veterinary cardiology for pet owners who want answers. Iâ€™m Dr. Dave Evans, and today weâ€™re talking about a hot topic in feline cardiology: Rapamycin. Also known by its new name: Felycin-CA1. Should you be giving it to your cat with HCM? Letâ€™s have a look.â€
Â 
First things first, I am making this video in the middle of 2025 and this is a fast changing topic, so be prepared for new information to appear. I will update my corresponding blog article, linked in the description below, as needed. Also vetcardiohub is totally independent, with no links to any of the researchers or pharmaceutical companies involved.

[Cut to: You speaking or animated title: â€œWhat is HCM?â€]
â€¨â€œHypertrophic cardiomyopathy, or HCM, is the most common heart condition in cats. It is a genetic condition that results in gradually progressive thickening of the heart muscle over time. Â Around 1 in 7 cats may be affected. But some cats show no symptoms. Others develop heart failure, blood clots, or even suffer sudden death.
Â 
Sadly, detection rates are still quite poor, and we still have little way to predict outcomesâ€
Â 
Visuals:
	â€¢	Animated cat with heart graphic
	â€¢	Pie chart showing 14% prevalence
	â€¢	Medical illustrations of a normal vs. thickened heart
	â€¢	Photo or video of a healthy, relaxed cat vs. one at the vet
Â 

[Cut to: â€œWhy Rapamycin?â€]
â€¨â€œRecently, a drug called Rapamycin â€” now conditionally approved in the US under the name Felycin-CA1 â€” has been gaining attention. It was originally developed as an anti-fungal and immune-modulating drug, but researchers discovered it also affects something called mTOR, a pathway involved in cell growth and stress.â€
Â 
Visuals:
	â€¢	Chemical structure of rapamycin (brief)
	â€¢	Animation: molecule interacting with a heart cell
	â€¢	Timeline: from antifungal to heart research
	â€¢	FDA â€œConditional Approvalâ€ stamp overlay
Â 
Â 

[Cut to: â€œHow Could It Help?â€]
â€¨â€œIn HCM, the heart muscle becomes abnormally thick. One theory is that this is caused by oxidative stress and a breakdown in normal cell recycling â€” something Rapamycin might help regulate. Thatâ€™s the science behind the hype.â€
Â 
Â 
Visuals:
	â€¢	Animation: heart muscle thickening over time
	â€¢	Keywords like â€œoxidative stressâ€ and â€œautophagyâ€ pop in
	â€¢	Animation of mTOR inhibition
	â€¢	Simplified â€œbefore and afterâ€ diagram of a heart muscle cell

[Cut to: RAPACAT trial chart visual]
â€¨â€œThe RAPACAT trial was a small but promising study. Forty-three cats with subclinical HCM were given either a placebo, a low dose, or a high dose of Rapamycin for 6 months. The result? Wall thickness increased in the placebo group â€” but stayed stable or slightly improved in the treatment groups.â€
Â 
Visuals:
	â€¢	List of limitations as animated bullet points:
	â—¦	â€œSmall study (43 cats)â€
	â—¦	â€œShort timeline (6 months)â€
	â—¦	â€œUnclear clinical outcomesâ€
	â€¢	Cat on an echocardiogram table
	â€¢	Subtle skeptical shrug emoji or animation
Â 

[Cut to: â€œSo... is it a wonder drug?â€]
â€¨â€œMaybe, maybe not. We really donâ€™t know yet. There are a few big caveats:
	â€¢	The trial was small â€” just 43 cats
	â€¢	It only ran for 6 months
	â€¢	It measured subtle changes in heart wall thickness â€” not actual outcomes like lifespan or quality of lifeâ€
As a cardiologist that sees lots of these cases, this is so far too short a timescale to make judgements on. Lots of cats spend years in this early phase of the disease. Also we donâ€™t tend to find the wall thickens and changes in a predictable way, or is even particularly related to the eventual outcomes â€“ either good or bad.
Â 
Visuals:
	â€¢	Blood glucose monitor animation
	â€¢	Vet drawing blood from a cat (stock clip)
	â€¢	Warning sign or â€œmonitor closelyâ€ message
	â€¢	Visual of a calendar for regular blood checks
Â 

[Cut to: â€œWhat about side effects?â€]
â€¨â€œOne of the treated cats developed diabetes â€” and glucose intolerance is a known side effect of Rapamycin in other species. So, if your cat is on it, regular bloodwork is a must. In my personal opinion, this risk of side effects with no convincing improvement in outcome is the real concern here. 

[Cut to: â€œOur Takeawayâ€]
â€¨â€œRight now, most cardiologists are cautiously optimistic â€” but not prescribing Rapamycin widely yet. We need longer studies with more cats to understand its real benefits and risks. If youâ€™re considering it, have a detailed conversation with your vet, and make sure your cat is being closely monitored.
Â 
I know a lot of you are desperately concerned for your catâ€™s wellbeing and we all urgently wish there was something to do that can safely and effectively slow or reduce this nasty disease. BUT -Â  I would strongly recommend waiting for a little more safety and efficacy data to come out before taking a gamble with your catâ€™s health.
Â 
Visuals:
	â€¢	Calm cat being examined by a vet
	â€¢	Overlay text: â€œTalk to your vet. Monitor regularly.â€
	â€¢	Chart showing treatment plan (visits, tests, signs to watch)
	â€¢	Optional: you speaking directly to camera
Â 
Â 

[Closing Scene â€” VetCardioHub logo & contact]
â€¨â€œThanks for watching VetCardioHub. If you found this helpful, hit like and subscribe for more clear, vet-led insight into your petâ€™s heart health. And remember â€” weâ€™re here to help you make the best choices for your beloved pets.â€
Â 
**Credits & Attributions:**
*â€Obstructive HCM diagramâ€ by Blausen.com staff (2014). "Medical gallery of Blausen Medical 2014".Â WikiJournal of MedicineÂ 1, licensed under CC BY 3.0 (https://creativecommons.org/licenses/by/3.0/).
*â€mTOR pathway diagramâ€ by Filip em, CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0/), via Wikimedia Commons
Â 
*RAPACAT Trial: Kaplan JL, Rivas VN, Walker AL, Grubb L, Farrell A, Fitzgerald S, Kennedy S, Jauregui CE, Crofton AE, McLaughlin C, Van Zile R, DeFrancesco TC, Meurs KM, Stern JA. â€œDelayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trialâ€. J Am Vet Med Assoc. 2023 Jul 26;261(11):1628-1637.
